Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan ’s health care system
ConclusionsINO versus SOC has higher costs but is more effective. The use of INO is favorable for patients in the early treatment course and when more future benefit associated with INO is considered.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Economics | Health Insurance | Health Management | Insurance | Leukemia | Stem Cell Therapy | Stem Cells | Study | Taiwan Health | Transplants